Kadimastem In the News

שיחה על הגישה שדוגלת בשילוב הטכנולוגיה הרפואה החדשנית של התנועה, עצות מעשיות לזיקנה רחוקה וטובה יותר. להארכת החיים ועיכוב הזיקנה ועל החשש הציבורי ממנה. אורח: פרופ' אריאל ראבל, מנהל רפאוי חברת קדימהסטם

​Avraham sat down with Asaf in the offices of Kadimastem to discuss how Kadimastem is creating and testing their innovative therapies, why Israeli startups are so successful, the role of patents in Kadimastem’s business, tips for startup founders and much more.

מערכת ספונסר
שיתוף הפעולה עם הדסית נוצר בשל היותה
מובילה בשיתוף פעולה עם חברות ומוסדות מחקר בינלאומיים, וטיפוח פיתוחים רפואיים פורצי דרך בהתאם לצרכי השוק

Making magic using the science of cell therapy is no longer theoretical, it’s actually happening.

CEO Asaf Shiloni talks candidly about the current state of the field and what to expect with Marjie Hadad in this article for Drug Discovery World.

A must read.

 Thank you Drug Discovery World Team.

 #STEMCELLTHERAPY #CELLTHERAPY #ALS  #Diabetes

The title of the article written by Catherine Longworth is Tackling diabetes & ALS with cell therapy! Kadimastem wants to thank Catherine for her time and interest in our cell therapy company and the important work we are doing here. "As the head of diabetes research at Israeli cell therapy company Kadimastem, Molakandov believes they could have the next major diabetes therapy. The Tel-Aviv listed company is leading research and development of a cell therapy comprising functional pancreatic islet cells."

Join Kadimastem in supporting the Israel ALS Association which works hard to help improve the quality of life of ALS patients, support them and their families, and fund medical research to find a cure for this insidious disease. 

Watch our short clip in support of IsrALS. We are ready! How about you?

Northeast walking hand in hand Conference in Maceió, Brazil. We will present AstroRx® cell therapy technology for the treatment of ALS patients; from bench to patient bedside!

Arik is Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel. Previously announced interim results demonstrated reduced disease progression in the first 3 months post-treatment period with AstroRx®. Click here for a link to the Meeting Site.

On diabetes awareness day, the world health bodies are focusing attention on making sure patients know how to manage their condition to prevent complications. We speak with a researcher who is working on developing a cure for the disease. Prof Ariel Revel

פרופ’ אריאל רבל מנהל המחקר בקדימהסטם: ” מחקר זה, מציע עדויות הולכות וגדלות לכך שאסטרוציטים ממלאים תפקיד חשוב ב ALS. ממצאים אלו פותחים אפשרות להתערבות. לצד תרופות שיכולות לחסום את תעלות החלבון הללו כדי שלא יפגעו בעצבי התנועה, כמו תרופה שפותחה במקור לטיפול במיגרנה ואפילפסיה קיים טיפול שנועד להחליף לחלוטין את האסטרוציטים הפגועים במחלה.

צפו בריאיון של פרופ' אריאל רבל, מנהל התחום הרפואי אצלנו, בריאיון מרתק יחד עם אור, חולת סוכרת נעורים בת 10. יחד הם מסבירים מה הם התסמינים, מה ההבדלים בין סוגי הסוכרת ואיך עובד הפיתוח שלנו לריפוי מחלת הסוכרת

Authority Mag specializes "In-depth interviews with Authorities in Business, Pop Culture, Wellness, Social Impact, and Tech. They use interviews to draw out stories that are both empowering and actionable."
Click here for the full story told by Michal Izrael in her in depth interview written by Penny Bauder.

May is ALS awareness month and Kadimastem is helping to bring awareness to as many as it can. Jobeth Devera interviewed our very own Michal Izrael PhD on the topic to share some important facts. Michal presented information  on the global impact ALS has, and how we can all help. We want to thank Jobeth and @NBCLX for hosting Kadimastem and shedding light on the work we are doing to try and bring some hope to those suffering and in need of treatment for ALS and other neurological diseases.

The ALS News Today published a very positive article written by Inês Martins, PhD who states: "A pooled analysis of all 10 patients included in the trial showed that AstroRx® reduced the disease progression rate by 53%" Read this informative article on our latest published findings from Interim of Cohort B in our phase 1/2a clinical trial on ALS patients. Click here to read the article. 

Kadimastem was pleased to be part of the amazing stem cell Community leading the path to innovative promising treatments. Using DASBox, Eppendorff. Click here for event details. 

The times of Israel article by Shoshanna Solomon writes that Israeli company Kadimastem says interim results of first patient group indicate new drug ‘managed to significantly slow down disease progression’. Click here for the full article. 

הסוף למחלת הסוכרת? קדימהסטם הינה חברה ישראלית המפתחת את IsletRx - טיפול מבוסס תאי גזע שיוכלו להחליף את תאי הלבלב אצל חולי סוכרת ולרפא את המחלה

האם קדימהסטם תשנה את עולם התרפיה התאים המיוצרת מתאי גזע? סיכום מכנס ישראל
בורסה האחרון
אורן בנימין

i24 news: "Israeli researchers recently developed a cellular therapy for Amyotrophic lateral sclerosis (ALS) that was successful in its first human clinical trial, providing a glimmer of hope for patients suffering from the disease."

A business and technology magazine based in Georgia, Atlanta, offering all reliable news and information from the industry straight to business leaders and professionals, has published an article : The Future of Healthcare: Revolutionizing Treatment for Any Disease with Stem Cell-based Cell Therapy.

See full article here

ALS News Today published an article by Marta Figueiredo in which she highlights the top ten most read articles on its website for 2020. Kadimastem's announcement on its completion of Cohort B and its preliminary efficacy results was rated second most read article of the year. We are grateful that our information is reaching the public and we will continue to update on out product results and progress. We have published 6 month follow up results of the second Cohort in December of 2020. 

The Jerusalem Post article by Maayan Jaffe-Hoffman illustrates our current clinical trial with AstroRx® for the treatment of ALS and its abilities to replace functioning of damages cells using allogenic "off the shelf" stem cells. Click here for the full article

NoCamels article by Simona Shemer writes about Israeli companies that are driving innovation in diabetes care and treatment, she writes about Kadimastem and our "off the shelf" product IsletRx in pre-clinical trials for the treatment of Type 1 Diabetes. Click here for the full article.